510 related items for PubMed ID: 17932598
1. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[Abstract] [Full Text] [Related]
2. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[Abstract] [Full Text] [Related]
3. [Early diagnosis of Kawasaki disease complicated by coronary artery lesions].
Hu XH, Xu SX, Luan Z.
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):853-5. PubMed ID: 12919919
[Abstract] [Full Text] [Related]
4. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[Abstract] [Full Text] [Related]
5. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[Abstract] [Full Text] [Related]
6. Expression of Fc<gamma>Rs on monocytes among Kawasaki disease patients with coronary artery lesions.
Xia Y, Tian X, Li Q, Wang G, Li C, Yang J.
Int Immunopharmacol; 2017 Apr; 45():1-5. PubMed ID: 28147297
[Abstract] [Full Text] [Related]
7. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[Abstract] [Full Text] [Related]
8. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
J Paediatr Child Health; 2004 Jan; 40(9-10):524-9. PubMed ID: 15367145
[Abstract] [Full Text] [Related]
9.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
10. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
11. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, Furukawa S.
Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
[Abstract] [Full Text] [Related]
12. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S, Safari M, Amin R.
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[Abstract] [Full Text] [Related]
13. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[Abstract] [Full Text] [Related]
14. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ, Kim KH, Chun JK, Kim DS.
Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
[Abstract] [Full Text] [Related]
15. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar 31; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
16. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec 31; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
17. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 31; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
18. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease.
Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, Kuroe K, Shimpo H, Nakano M, Komada Y.
Circulation; 2005 Jan 04; 111(1):38-43. PubMed ID: 15611368
[Abstract] [Full Text] [Related]
19. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb 04; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
20. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
Pediatr Allergy Immunol; 2007 Jun 04; 18(4):354-9. PubMed ID: 17584314
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
